AquaBounty Technologies, Inc. (NASDAQ:AQB) Sees Significant Decrease in Short Interest

AquaBounty Technologies, Inc. (NASDAQ:AQB) was the target of a large drop in short interest during the month of August. As of August 15th, there was short interest totalling 68,800 shares, a drop of 9.4% from the July 31st total of 75,900 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average daily trading volume, of 21,700 shares, the short-interest ratio is presently 3.2 days.

AquaBounty Technologies Trading Up 3.5 %

NASDAQ AQB traded up $0.04 on Monday, reaching $1.03. The stock had a trading volume of 70,200 shares, compared to its average volume of 24,833. AquaBounty Technologies has a 12-month low of $0.81 and a 12-month high of $6.13. The stock has a fifty day moving average price of $1.46 and a two-hundred day moving average price of $1.80. The firm has a market capitalization of $3.97 million, a price-to-earnings ratio of -0.12 and a beta of 1.18. The company has a quick ratio of 1.96, a current ratio of 1.96 and a debt-to-equity ratio of 0.05.

AquaBounty Technologies (NASDAQ:AQB) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.63). AquaBounty Technologies had a negative net margin of 3,923.57% and a negative return on equity of 17.81%. The firm had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, sell-side analysts forecast that AquaBounty Technologies will post -4.86 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of AquaBounty Technologies in a report on Thursday, May 16th.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc, a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts.